Lost in translation: Epidemiology, risk, and alzheimer disease

Archives of Neurology

Volumn 67, Issue 1, 2010, Pages 107-111

  Ganguli, Mary ^a   Kukull, Walter A ^b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CHOLESTEROL; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEMENTIA; GENETIC RISK; HUMAN; MEDICAL RESEARCH; NEUROPROTECTION; NOTE; PREDICTIVE VALIDITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SMOKING CESSATION;

ALZHEIMER DISEASE; CAUSALITY; CLINICAL TRIALS AS TOPIC; COMMUNITY-INSTITUTIONAL RELATIONS; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGIC METHODS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; INTERDISCIPLINARY COMMUNICATION; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; TRANSLATIONAL RESEARCH;

EID: 74949102893     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.311     Document Type: Note

References (30)

1. Zerhouni EA. Translational and clinical science: time for a new vision. N Engl J Med. 2005;353(15):1621-1623.
2. Hodes RJ. Public funding for Alzheimer disease research in the United States. Nat Med. 2006;12(7):770-773.
3. Zandi PP, Carlson MC, Plassman BL, et al; Cache County Memory Study Investigators. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA. 2002;288(17):2123-2129.
4. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291(24):2947- 2958.
5. Lyketsos CG, Breitner JC, Green RC, et al; ADAPT Research Group. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68(21):1800-1808.
6. Breitner JCS, Haneuse SJPA, Walker R, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology. 2009;72(22):1899-1905.
7. Petersen RC, Thomas RG, Grundman M, et al; Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379-2388.
8. Sano M, Grossman H, Van Dyk K. Preventing Alzheimer's disease: separating fact from fiction. CNS Drugs. 2008;22(11):887-902.
9. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia [update of: CochraneDatabase SystRev. 2001;(4):CD003160]. Cochrane Database Syst Rev. 2009;(2):CD003160.
10. Tatsioni A, Bonitsis NG, Ioannidis JP. Persistence of contradicted claims in the literature. JAMA. 2007;298(21):2517-2526.
11. Koepsell TD, Weiss NS. Epidemiologic Methods: Studying the Occurrence of Illness. New York, NY: Oxford University Press; 2003.
12. Hachinski V. The 2005 Thomas Willis Lecture: stroke and vascular cognitive impairment: a transdisciplinary, translational and transactional approach. Stroke. 2007;38(4):1396-1403.
13. Kivipelto M, Helkala E-L, Laakso M, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001;322(7300):1447-1451.
14. Mielke MM, Zandi PP, Sjögren M, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology. 2005;64(10):1689-1695.
15. in 'T Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345(21):1515-1521.
16. Brayne C. The elephant in the room: healthy brains in later life, epidemiology and public health. Nat Rev Neurosci. 2007;8(3):233-239.
17. Gureje O, Ogunniyi A, Baiyewu O. APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians. Ann Neurol. 2006;59(1):182-185.
18. Farrer LA, Cupples LA, Haines JL, et al; APOE and Alzheimer Disease Meta Analysis Consortium. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278(16):1349-1356.
19. Mayeux R, Ottman R, Maestre G, et al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon4 in patients with Alzheimer's disease. Neurology. 1995;45(3, pt 1):555-557.
20. O'Meara ES, Kukull WA, Sheppard L, et al. Head injury and risk of Alzheimer's disease by apolipoprotein E genotype. Am J Epidemiol. 1997;146(5):373-384.
21. Qiu C, Winblad B, Fastbom J, Fratiglioni L. Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD. Neurology. 2003;61(5):655-660.
22. Ganguli M,DuY, Dodge HH, Ratcliff GG, Chang CC. Depressive symptoms and cognitive decline in late life: a prospective epidemiological study. Arch Gen Psychiatry. 2006;63(2):153-160.
23. Barnes DE, Alexopoulos GS, Lopez OL, Williamson JD, Yaffe K. Depressive symptoms, vascular disease and mild cognitive impairment: findings from the Cardiovascular Health Study. Arch Gen Psychiatry. 2006;63(3):273-279.
24. Speck CE, Kukull WA, Brenner DE, et al. History of depression as a risk factor for Alzheimer's disease. Epidemiology. 1995;6(4):366-369.
25. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160(8):1516-1518.
26. Rapp MA, Schnaider-Beeri M, Grossman HT, et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry. 2006;63(2):161-167.
27. Checkley S. The neuroendocrinology of depression and chronic stress. Br Med Bull. 1996;52(3):597-617.
28. Bennett DA, Whitmer RA. NSAID exposure and risk of Alzheimer disease: is timing everything? Neurology. 2009;72(22):1884-1885.
29. Greenland S, Gago-Dominguez M, Castelao JE. The value of risk-factor ("black-box") epidemiology. Epidemiology. 2004;15(5):529-535.
30. West SG, Duan N, Pequegnat W, et al. Alternatives to the randomized controlled trial. Am J Public Health. 2008;98(8):1359-1366.